Zhitong Finance App News, Taienkang (301263.SZ) issued an announcement. Recently, the Phase IIa clinical trial of the Class 1 innovative drug CKBA cream developed independently by Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., the holding subsidiary of the company, has recently completed data compilation. Preliminary analysis results showed that 1.50% CKBA cream was effective and safe in treating moderate to severe papular pustular rosacea. The proportion of subjects with an overall evaluation (IGA) score of 0 or 1 after 16 weeks of treatment was 60.00% (9/15), and the inflammatory skin damage count (ILC) decreased by 39.06 compared to the baseline, a decrease of 76.40%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.